A61P 1 - Drugs for disorders of the alimentary tract or the digestive system

Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
10/2001
10/23/2001	US6306881 Anti-inflammatory agents
10/23/2001	US6306879 Isotonic glucose solution
10/23/2001	US6306876 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives
10/23/2001	US6306863 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
10/23/2001	US6306854 Chemical compounds
10/23/2001	US6306840 Cell adhesion inhibitors
10/23/2001	US6306838 Targeted vesicular constructs for cyto protection and treatment of h. pylori
10/23/2001	US6306655 Antisense inhibition of C/EBP alpha expression
10/23/2001	US6306579 Immunoassay by incubating sample with at least one peptide from ns3 region having at least one covalently modified cysteine or replaced cysteine, then determining binding of antibody to peptide
10/23/2001	US6306398 Delipidating plant powder by extraction of powder with a solution containing organic solvent; separating powder from organic solvent; extracting delipidated powder with solvent or phosphate buffered saline; separation to obtain retentate
10/23/2001	US6306392 Prevention and/or treatment of alterations of those organs which perform metabolic function, such as liver, kidneys, cardiovascular system and brain; for therapy of hepatosis, nephropathies and cardiovascular or cerebral damage damage
10/23/2001	CA2222657C Intermediates in preparation of new phenylethanolaminomethyltetralins
10/23/2001	CA2087606C (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
10/18/2001	WO2001077685A2 Diagnosis and treatment of gastrointestinal disease
10/18/2001	WO2001077681A1 Tpst-assay for diagnosis of autism and related disorders
10/18/2001	WO2001077327A1 THE HIGH BONE MASS GENE OF 11q13.3
10/18/2001	WO2001077326A1 Novel g protein-coupled receptor protein and dna thereof
10/18/2001	WO2001077174A2 Human transporters and ion channels
10/18/2001	WO2001077158A1 Hepatitis b core antigen fusion proteins
10/18/2001	WO2001077149A2 Regulation of human cyslt2-like gpcr protein
10/18/2001	WO2001077139A1 8ss-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS
10/18/2001	WO2001077138A1 8β-SUBSTITUTED-11β-PENTYL- AND 11β-HEXYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES
10/18/2001	WO2001077137A1 Albumin fusion proteins
10/18/2001	WO2001077110A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
10/18/2001	WO2001077109A2 Sodium salt of an azo derivative of 5-aminosalicylic acid
10/18/2001	WO2001077108A1 Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them
10/18/2001	WO2001077104A1 Bicyclic heterocylces, medicaments containing said compounds, the use thereof and method for producing them
10/18/2001	WO2001077101A1 Chemical compounds
10/18/2001	WO2001077100A2 Benzoamide piperidine compounds as substance p antagonists
10/18/2001	WO2001077092A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/18/2001	WO2001077087A1 Novel compounds
10/18/2001	WO2001077073A1 Cathepsin cysteine protease inhibitors
10/18/2001	WO2001077069A1 Naphthamide neurokinin antagonists for use as medicaments
10/18/2001	WO2001076631A2 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
10/18/2001	WO2001076604A1 Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
10/18/2001	WO2001076593A2 Bile secretion promoting composition a 15-keto prostaglandin
10/18/2001	WO2001076580A1 Remedies
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076568A2 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/18/2001	WO2001076554A2 Drug delivery composition and device
10/18/2001	WO2001076530A2 Il-8 receptor antagonists
10/18/2001	WO2001076381A1 Protein stabilised emulsions
10/18/2001	WO2001038316A3 Sulfonyl oxazole amines and their use as 5-ht6 receptor ligands
10/18/2001	WO2001026737A3 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator
10/18/2001	WO2001023388A3 AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES
10/18/2001	WO2001020004A3 Protein phosphatase and kinase proteins
10/18/2001	WO2000043498A9 Human liver progenitors
10/18/2001	WO2000039283A9 Use of cd40 engagement to alter t cell receptor usage
10/18/2001	US20010031870 Benzamide and sulfonamide substitued aminoguanidines and alkoxyguanidines as protese inhibitors
10/18/2001	US20010031782 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
10/18/2001	US20010031777 Heterocyclic compounds and their therapeutic use
10/18/2001	US20010031766 Prostaglandin receptor ligands
10/18/2001	US20010031763 Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents
10/18/2001	US20010031757 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, N'-((1-(Aminoiminomethyl)4-piperidinyl) methyl)-N-(3,3- diphenylpropionyl)-L-proline amide
10/18/2001	US20010031733 Compound B as angiogenic agent in combination with human growth factors
10/18/2001	US20010031265 Soaking in solution; then culturing
10/18/2001	US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders
10/18/2001	DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma
10/18/2001	CA2409782A1 Drug delivery composition and device
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001	CA2405004A1 Therapeutically useful new salts of cck inhibitors, process for the preparation thereof and pharmaceutical preparations containing them
10/18/2001	CA2404915A1 Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
10/18/2001	CA2404889A1 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
10/18/2001	CA2404852A1 Diagnosis and treatment of gastrointestinal disease
10/18/2001	CA2404630A1 Cathepsin cysteine protease inhibitors
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2403012A1 Chemical compounds
10/18/2001	CA2402410A1 The high bone mass gene of 11q13.3
10/18/2001	CA2372352A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/17/2001	EP1145715A2 Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
10/17/2001	EP1145714A1 Drugs
10/17/2001	EP1145644A2 Glycoprotein having inhibitory activity against helicobacter pylori colonization
10/17/2001	EP1145001A2 (in vitro) model for gastrointestinal inflammation
10/17/2001	EP1144682A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
10/17/2001	EP1144673A1 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith
10/17/2001	EP1144648A1 Cyclic nucleotide-associated proteins
10/17/2001	EP1144614A2 33 human secreted proteins
10/17/2001	EP1144600A2 Akt-3 nucleic acids, polypeptides, and uses thereof
10/17/2001	EP1144598A2 Human homologues of proteins regulated by circadian rhythms
10/17/2001	EP1144450A1 Mammalian alpha-helical protein - 12
10/17/2001	EP1144446A1 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
10/17/2001	EP1144443A2 Human membrane transport proteins
10/17/2001	EP1144435A2 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144431A2 16-hydroxyestratrienes as selective estrogens
10/17/2001	EP1144413A1 2,5-diazabicyclo 2.2.1]heptane derivatives, their preparation and therapeutic uses
10/17/2001	EP1144409A2 Phenyl urea and phenyl thiourea derivatives
10/17/2001	EP1144403A1 Substitued pyrazoles as p38 kinase inhibitors
10/17/2001	EP1144402A2 Substituted oximes and hydrazones as neurokinin antagonists
10/17/2001	EP1144395A1 2-amino-benzoxazinone derivatives for the treatment of obesity
10/17/2001	EP1144394A1 1-heterocycle substituted diarylamines
10/17/2001	EP1144393A2 Heterocyclic derivatives and their use as integrin inhibitor
10/17/2001	EP1144390A2 Kinase inhibitors
10/17/2001	EP1144388A1 Acyl derivatives which treat vla-4 related disorders
10/17/2001	EP1144387A1 New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
10/17/2001	EP1144386A1 Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
10/17/2001	EP1144384A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
10/17/2001	EP1144369A2 Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/17/2001	EP1144368A2 Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors
10/17/2001	EP1144365A2 Inhibitors of alpha-4 beta-1 mediated cell adhesion

1 ... 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 ... 1258